Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 1

Status

Terminated 2Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 7Observational 4

Sponsor

Cancer Type

Breast 7Gastrointestinal 1

Conditions

Breast Neoplasms 2400Neoplasms 1819Carcinoma, Non-Small-Cell Lung 1599Prostatic Neoplasms 1298Colorectal Neoplasms 1140Lung Neoplasms 984Neoplasm Metastasis 830Multiple Myeloma 792Leukemia, Myeloid, Acute 767Ovarian Neoplasms 674Pancreatic Neoplasms 662Melanoma 660Squamous Cell Carcinoma of Head and Neck 586Carcinoma, Hepatocellular 567Recurrence 562Brain Neoplasms 527Glioblastoma 513Head and Neck Neoplasms 500Stomach Neoplasms 497Triple Negative Breast Neoplasms 465Lymphoma 454Uterine Cervical Neoplasms 450Carcinoma, Renal Cell 425Precursor Cell Lymphoblastic Leukemia-Lymphoma 410Lymphoma, Non-Hodgkin 389Endometrial Neoplasms 381Sarcoma 368Lymphoma, Follicular 356Urinary Bladder Neoplasms 354Hematologic Neoplasms 352

Interventions

Fulvestrant 3Letrozole 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1ribociclib 1pegfilgrastim 1exemestane 1abemaciclib 1Zoledronic Acid 1Tamoxifen 1Paclitaxel 1Neoadjuvant Therapy 1Gemcitabine 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Breast Cancer Metastatic × 1 year × Clear all
NCT06750484 2026-05-06

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Yale University

Phase 2 Recruiting
40 enrolled
Breast

Breast Cancer Metastatic

NCT04059484 2026-02-24

AMEERA-3

Sanofi

Phase 2 Terminated
367 enrolled 30 charts
Breast

Breast Cancer Metastatic

NCT06849947 2025-12-24

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Samsung Medical Center

Phase 2 Not yet recruiting
272 enrolled
Breast

Breast Cancer Metastatic

NCT04603183 2025-12-12

ABIGAIL

MedSIR

Phase 2 Completed
162 enrolled
Breast

Breast Cancer Metastatic

NCT04659603 2025-10-01

CARMEN-BT01

Sanofi

Phase 2 Terminated
50 enrolled 20 charts
BreastGastrointestinal

Breast Cancer Metastatic

NCT06616987 2025-08-28

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Samsung Medical Center

Phase 2 Recruiting
40 enrolled
Breast

Breast Cancer Metastatic

NCT06876636 2025-07-29

Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer

Xijing Hospital

Phase NA Active not recruiting
99 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡